• Profile
EGFR-TKI in NSCLC – How do we manage them in India?
Date: Sat 31 Aug, 2019 2:00–3:00pm
Duration: 1 hour


The session will cover:

  • Lung cancer burden in India and the world
  • How common is EGFR mutation in India
  • Tests for EGFR mutations
  • First line treatment option
  • Re-biopsy
  • Reason for resistance
  • Second line treatment option
  • Third line treatment option
  • The difference that we have made in the outcome
About the presenter:
Picture1 1565350357 1565613242 1565692896
Dr. Kumar Prabhash, Professor of Medical Oncology at Tata Memorial Hospital, Mumbai
  • His career has taken him through 25 years of study, research, teaching and administration in this field in various capacities
  • He has promulgated various initiatives and patient programs
  • He is the recipient of Madam Curie fellowship as well as the IAEA Fellowship
  • He has been a recipient of the MOSCON award
  • He has been an invited speaker at ASCO
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen